RxDoctor Payments Data

Maile Young, MD

Internal Medicine · San Diego, CANPI 1093904997

Payments from drug & device makers

$6,483in general payments, 2019–2025

Across 90 payments — averaging $72.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • Viiv Healthcare Company$2K
  • Johnson & Johnson$438
  • Merck$54
  • Theratechnologies Inc.$20

What the payments were for

  • Consulting fees$4,55070%
  • Travel & lodging$1,02216%
  • Food & beverage$89014%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,483 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$20,084
Medicare patients
76
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala263$986,312
DovatoDolutegravir Sodium/Lamivudine68$189,422
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf39$171,824
TivicayDolutegravir Sodium74$152,451
TriumeqAbacavir/Dolutegravir/Lamivudi33$144,584
PrezcobixDarunavir/Cobicistat59$138,853
DescovyEmtricitabine/Tenofov Alafenam42$128,374
CabenuvaCabotegravir/Rilpivirine19$107,562
RukobiaFostemsavir Tromethamine13$102,834
PifeltroDoravirine52$101,195
XifaxanRifaximin21$65,001
Combivent RespimatIpratropium/Albuterol Sulfate30$14,152
OzempicSemaglutide13$11,478
FarxigaDapagliflozin Propanediol16$11,474
EliquisApixaban15$8,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$3,583$1,114,686305 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Cabenuva, Rukobia$2,388$696,853207 claims
Johnson & JohnsonPrezcobix, Xarelto$438$146,33571 claims
MerckPifeltro$54$101,19552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →